Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1579416 | 0.71 | RECQL (0.37) | RECQL | |
| SCHEMBL6296325 | 0.69 | ALPL (0.33) | RECQL | |
| SCHEMBL18270102 | 0.69 | LMNA (0.30) | — | |
| SCHEMBL17924952 | 0.67 | RECQL (0.34) | RECQL | |
| SCHEMBL29703853 | 0.67 | RECQL (0.30) | RECQL | |
| SCHEMBL14829355 | 0.67 | RECQL (0.30) | RECQL | |
| SCHEMBL530755 | 0.67 | RECQL (0.30) | RECQL | |
| SCHEMBL17931188 | 0.65 | ALOX15 (0.33) | — | |
| SCHEMBL135914 | 0.64 | — | — | |
| SCHEMBL3524614 | 0.63 | ALOX15 (0.41) | RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903117-B2 | Indole derivatives for the treatment of osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2005-06-07 | — | — | US | disclosed |
| US-20040010012-A1 | Selective inhibitor of the biological activity of human osteoclast cells | SMITHKLINE BEECHAM SPA | 2004-01-15 | — | — | US | disclosed |
| US-20020173659-A1 | Indole derivatives for the treatment of osteoporosis | SMITH KLINE BEECHAM SPA | 2002-11-21 | — | — | US | disclosed |
| CN-1241184-A | Indole derivatives for the treatment of osteoporosis | SMITHKLINE BEECHAM SPA (IT) | 2000-01-12 | — | — | CN | disclosed |
| US-5981525-A | FOR THERAPY OR PROPHYLAXIS OF OSTEOPOROSIS,TUMOURS, ULCERS, AUTOIMMUNE DISEASES, LIPIDEMIC DISORDERS, HYPERCHOLESTEROLEMIC AND ATHEROSCLEROTIC DISEASES, AIDS ALZHEIMER'S DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0914321-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS | Smithkline Beecham S.p.A. (IT) | 1999-05-12 | — | — | EP | disclosed |
| CN-1177957-A | Indole derivatives for the treatment of osteoporosis | SMITHKLINE BEECHAM SPA (IT) | 1998-04-01 | — | — | CN | disclosed |
| WO-1998001443-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS | SMITHKLINE BEECHAM S.P.A. (IT) | 1998-01-15 | — | — | WO | disclosed |
| EP-0802902-A1 | INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF OSTEOPOROSIS | Smithkline Beecham S.p.A. (IT) | 1997-10-29 | — | — | EP | disclosed |
| WO-1996021644-A1 | INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF OSTEOPOROSIS | SMITHKLINE BEECHAM S.P.A. (IT) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010012-A1 | Selective inhibitor of the biological activity of human osteoclast cells | HRH4, HRH3, CNKSR1 | RECQL 3503/4885 |
| US-20020173659-A1 | Indole derivatives for the treatment of osteoporosis | SOST, GHRHR, EBP | RECQL 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.